335 related articles for article (PubMed ID: 1972053)
1. [Clozapine and resistant schizophrenia].
Pere JJ; Chaumet-Riffaud D
Encephale; 1990; 16(2):143-5. PubMed ID: 1972053
[TBL] [Abstract][Full Text] [Related]
2. Clozapine: an atypical antipsychotic agent.
Ereshefsky L; Watanabe MD; Tran-Johnson TK
Clin Pharm; 1989 Oct; 8(10):691-709. PubMed ID: 2572373
[TBL] [Abstract][Full Text] [Related]
3. Clozapine.
Jann MW
Pharmacotherapy; 1991; 11(3):179-95. PubMed ID: 1677765
[TBL] [Abstract][Full Text] [Related]
4. Novel pharmacological approaches to the treatment of schizophrenia.
Fink-Jensen A
Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
[TBL] [Abstract][Full Text] [Related]
5. Clozapine for refractory schizophrenia: an open study of 14 patients treated up to 2 years.
Mattes JA
J Clin Psychiatry; 1989 Oct; 50(10):389-91. PubMed ID: 2571612
[TBL] [Abstract][Full Text] [Related]
6. The risks and benefits of clozapine versus chlorpromazine.
Claghorn J; Honigfeld G; Abuzzahab FS; Wang R; Steinbook R; Tuason V; Klerman G
J Clin Psychopharmacol; 1987 Dec; 7(6):377-84. PubMed ID: 3323261
[TBL] [Abstract][Full Text] [Related]
7. Should chronic treatment-refractory akathisia be an indication for the use of clozapine in schizophrenic patients?
Levin H; Chengappa KN; Kambhampati RK; Mahdavi N; Ganguli R
J Clin Psychiatry; 1992 Jul; 53(7):248-51. PubMed ID: 1353492
[TBL] [Abstract][Full Text] [Related]
8. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis.
Small JG; Milstein V; Marhenke JD; Hall DD; Kellams JJ
J Clin Psychiatry; 1987 Jul; 48(7):263-7. PubMed ID: 2885310
[TBL] [Abstract][Full Text] [Related]
9. Dopaminergic and serotonergic effects of clozapine. Implications for a unique clinical profile.
Meltzer HY; Gudelsky GA
Arzneimittelforschung; 1992 Feb; 42(2A):268-72. PubMed ID: 1586397
[TBL] [Abstract][Full Text] [Related]
10. Clozapine: guidelines for clinical management.
Lieberman JA; Kane JM; Johns CA
J Clin Psychiatry; 1989 Sep; 50(9):329-38. PubMed ID: 2670914
[TBL] [Abstract][Full Text] [Related]
11. [The atypical neuroleptic clozapine (Leponex)--current knowledge and recent clinical aspects].
Klimke A; Klieser E
Fortschr Neurol Psychiatr; 1995 May; 63(5):173-93. PubMed ID: 7782019
[TBL] [Abstract][Full Text] [Related]
12. Computerized EEG profiles of haloperidol, chlorpromazine, clozapine and placebo in treatment resistant schizophrenia.
Small JG; Milstein V; Small IF; Miller MJ; Kellams JJ; Corsaro CJ
Clin Electroencephalogr; 1987 Jul; 18(3):124-35. PubMed ID: 3652464
[TBL] [Abstract][Full Text] [Related]
13. [Clozapine--an atypical antipsychotic agents, its advantages and risks].
Zvolský P; Hulínský J
Cesk Psychiatr; 1994 Dec; 90(6):328-40. PubMed ID: 7859323
[TBL] [Abstract][Full Text] [Related]
14. [New chemotherapy approaches to psychoses].
Olié JP; Baylé FJ
Encephale; 1997 Apr; 23 Spec No 2():2-9. PubMed ID: 9273302
[TBL] [Abstract][Full Text] [Related]
15. Role of serotonin in the action of atypical antipsychotic drugs.
Meltzer HY
Clin Neurosci; 1995; 3(2):64-75. PubMed ID: 7583621
[TBL] [Abstract][Full Text] [Related]
16. Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia.
Bishnoi M; Kumar A; Chopra K; Kulkarni SK
Indian J Exp Biol; 2007 Feb; 45(2):175-9. PubMed ID: 17375557
[TBL] [Abstract][Full Text] [Related]
17. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Kumagai T; Nakazato A; Nagamine M; Yamaguchi K; Tomisawa K
Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
[TBL] [Abstract][Full Text] [Related]
18. [Dopamine D4-receptor variants, schizophrenia and clozapine therapy].
Ewald HL; Mors NP; Rosenberg R
Ugeskr Laeger; 1996 Jun; 158(25):3601-3. PubMed ID: 8693618
[TBL] [Abstract][Full Text] [Related]
19. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents.
Millan MJ; Brocco M; Rivet JM; Audinot V; Newman-Tancredi A; Maiofiss L; Queriaux S; Despaux N; Peglion JL; Dekeyne A
J Pharmacol Exp Ther; 2000 Jan; 292(1):54-66. PubMed ID: 10604931
[TBL] [Abstract][Full Text] [Related]
20. Clozapine: the commitment to patient safety.
Alphs LD; Anand R
J Clin Psychiatry; 1999; 60 Suppl 12():39-42. PubMed ID: 10372610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
